Not exact matches
The
blockade of
immune checkpoints with
antibodies (Ab) anti-CTLA-4, anti-PD1 and anti-PD-L1, has given impressive clinical results and manageable safety profiles.
In addition to
checkpoint blockade antibodies, the editors also pointed to recent advances in adoptive cell therapy — removing a patient's
immune cells, engineering them in the lab, and then re-infusing them back into the patient to fight cancer.
Allison is the person responsible for developing the
checkpoint blockade approach to cancer immunotherapy:
antibodies are used to target specific molecules on
immune cells, which empowers them to find and attack cancer cells.
Along with
checkpoint blockade antibodies, vaccines, and other immunotherapies, BiTEs are helping to turn our
immune system into a powerful defense against this disease.